Purpose: Keratitis-ichthyosis-deafness (KID) syndrome is a rare congenital ectodermal dysplastic syndrome presenting with keratitis, ichthyosis and sensorineural hearing loss. The most common causes of KID syndrome are heterozygous missense mutations in the gene that codes for connexin 26.

Case Report: During the ophthalmological examination, two adult females complained of recent worsening of visual acuity in both eyes. Anamnesis revealed that their eyes were red and irritated from early childhood onwards. Both of them had thickening and keratinisation of eyelid margins, lash loss, diffuse opacification of cornea and conjunctiva caused by keratinisation of eye surface, superficial and deep corneal vascularisation and corneal oedema. Partial sensorineural hearing loss and difficulties in speech were also noted along with typical ichthyosiform erythroderma. Genetic testing of the gene revealed a heterozygous p.D50N mutation in both patients.Patients were treated with a combined topical corticosteroid and artificial tears therapy, with steroid therapy being intensified during the last month. The therapy increased the visual acuity by decreasing corneal oedema and by forming a more regular air-tear interface during the six months follow up. Subsequently, the disease progressed despite the continuation of the therapy.

Conclusion: This is the first report of Serbian patients with KID syndrome. Despite the administration of the combined topical corticosteroid and artificial tears therapy the disease is relentlessly progressive and therapeutic success of ophthalmological signs with local therapeutic modalities used so far had been disappointing.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985354PMC
http://dx.doi.org/10.2478/bjmg-2022-0014DOI Listing

Publication Analysis

Top Keywords

kid syndrome
12
syndrome heterozygous
8
heterozygous pd50n
8
sensorineural hearing
8
hearing loss
8
visual acuity
8
corneal oedema
8
combined topical
8
topical corticosteroid
8
corticosteroid artificial
8

Similar Publications

Keratitis-ichthyosis-deafness syndrome (KID) is a rare genetic disorder characterized by the triad of hyperkeratosis, ichthyosis, and congenital prelingual sensorineural deafness, with less than 100 cases described in the literature. In addition to many other extra-cutaneous manifestations, these patients are burdened by two principal increased risk factors involving the skin: the risk of developing infections and the risk of developing malignant skin tumors, especially Squamous Cell Carcinoma and Trichilemmal tumors. We present the case of a 7-year-old girl with a unique genetic variant described to date, who developed 4 dyskeratotic neoformation.

View Article and Find Full Text PDF

We describe a 1-day old female with features of keratitis-ichthyosis-deafness (KID) syndrome and natal teeth. Genetic analysis confirmed GJB2 263C and A88V de novo pathogenic variants consistent with KID syndrome. Natal teeth were promptly extracted to avoid the risk of aspiration.

View Article and Find Full Text PDF

Connexin Hemichannel Inhibition and Human Genodermatoses.

J Invest Dermatol

September 2024

Department of Physiology and Biophysics, Stony Brook University School of Medicine, Stony Brook, New York, USA. Electronic address:

Article Synopsis
  • * Studies suggest that blocking this increased hemichannel activity might help reduce skin-related symptoms.
  • * Research in mouse models shows that using specific inhibitors is a promising strategy for developing new treatments for KID and HED, and could also benefit other similar genetic skin conditions.
View Article and Find Full Text PDF

Hyperkeratotic Nodule on the Knee in a Patient With KID Syndrome.

Cutis

March 2024

Peichi Chou is from the School of Medicine, University of California, Riverside. Drs. Lee and Elsensohn are from the Department of Dermatology, Loma Linda University, California.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the effectiveness and safety of mycophenolate mofetil (MMF) in treating ocular surface inflammatory diseases through a retrospective analysis of patient records from March 2020 to March 2022.
  • Fourteen patients participated, primarily diagnosed with ocular mucous membrane pemphigoid and those requiring limbal allograft transplantation, with results showing significant improvement and stability in most cases treated with MMF.
  • The treatment proved generally safe, with only minor side effects like constipation and nausea reported, indicating that MMF could be a promising first-line systemic treatment for these eye conditions.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!